463 related articles for article (PubMed ID: 23381014)
1. Anti-diabetic medications and the risk of hepatocellular cancer: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; Sanchez W
Am J Gastroenterol; 2013 Jun; 108(6):881-91; quiz 892. PubMed ID: 23381014
[TBL] [Abstract][Full Text] [Related]
2. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Singh S; Singh PP; Singh AG; Murad MH; McWilliams RR; Chari ST
Am J Gastroenterol; 2013 Apr; 108(4):510-9; quiz 520. PubMed ID: 23399556
[TBL] [Abstract][Full Text] [Related]
3. Anti-diabetic medications do not influence risk of lung cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Nie SP; Chen H; Zhuang MQ; Lu M
Asian Pac J Cancer Prev; 2014; 15(16):6863-9. PubMed ID: 25169538
[TBL] [Abstract][Full Text] [Related]
4. Antidiabetic medications and the risk of colorectal cancer in patients with diabetes mellitus: a systematic review and meta-analysis.
Singh S; Singh H; Singh PP; Murad MH; Limburg PJ
Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2258-68. PubMed ID: 24042261
[TBL] [Abstract][Full Text] [Related]
5. Thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, sulfonylureas, and hepatocellular carcinoma risk: A meta-analysis.
Arvind A; Memel ZN; Philpotts LL; Zheng H; Corey KE; Simon TG
Metabolism; 2021 Jul; 120():154780. PubMed ID: 33891949
[TBL] [Abstract][Full Text] [Related]
6. Antidiabetic Medications and the Risk of Endometrial Cancer in Patients.
Tian J; Liang Y; Qu P
Gynecol Obstet Invest; 2019; 84(5):455-462. PubMed ID: 30808843
[TBL] [Abstract][Full Text] [Related]
7. Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.
Wu Y; Liu HB; Shi XF; Song Y
PLoS One; 2014; 9(6):e99577. PubMed ID: 24924771
[TBL] [Abstract][Full Text] [Related]
8. Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies.
Wu L; Zhu J; Prokop LJ; Murad MH
Sci Rep; 2015 Jun; 5():10147. PubMed ID: 26076034
[TBL] [Abstract][Full Text] [Related]
9. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis.
Zhang H; Gao C; Fang L; Zhao HC; Yao SK
Scand J Gastroenterol; 2013 Jan; 48(1):78-87. PubMed ID: 23137049
[TBL] [Abstract][Full Text] [Related]
10. Association between hepatocellular carcinoma and type 2 diabetes mellitus in Italy: potential role of insulin.
Donadon V; Balbi M; Casarin P; Vario A; Alberti A
World J Gastroenterol; 2008 Oct; 14(37):5695-700. PubMed ID: 18837086
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: The efficacy of metformin and other anti-hyperglycemic agents in prolonging the survival of hepatocellular carcinoma patients with type 2 diabetes.
Zhou J; Ke Y; Lei X; Wu T; Li Y; Bao T; Tang H; Zhang C; Wu X; Wang G; Li J; Zhang H; Ni F; Ye Z; Wang L
Ann Hepatol; 2020; 19(3):320-328. PubMed ID: 31980358
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.
van Dalem J; Driessen JHM; Burden AM; Stehouwer CDA; Klungel OH; de Vries F; Brouwers MCGJ
Hepatology; 2021 Nov; 74(5):2467-2477. PubMed ID: 34129693
[TBL] [Abstract][Full Text] [Related]
13. Risk of hepatocellular carcinoma in diabetic patients and risk reduction associated with anti-diabetic therapy: a population-based cohort study.
Lai SW; Chen PC; Liao KF; Muo CH; Lin CC; Sung FC
Am J Gastroenterol; 2012 Jan; 107(1):46-52. PubMed ID: 22085817
[TBL] [Abstract][Full Text] [Related]
14. Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.
Mekuria AN; Ayele Y; Tola A; Mishore KM
J Diabetes Res; 2019; 2019():7676909. PubMed ID: 31828167
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemic agents and incidence of pancreatic cancer in diabetic patients: a meta-analysis.
Zhao Z; He X; Sun Y
Front Pharmacol; 2023; 14():1193610. PubMed ID: 37497113
[No Abstract] [Full Text] [Related]
16. Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.
Donadon V; Balbi M; Mas MD; Casarin P; Zanette G
Liver Int; 2010 May; 30(5):750-8. PubMed ID: 20331505
[TBL] [Abstract][Full Text] [Related]
17. Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis.
Xin WX; Fang L; Fang QL; Zheng XW; Ding HY; Huang P
Medicine (Baltimore); 2018 Mar; 97(9):e0035. PubMed ID: 29489653
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk associated with the use of glitazones, metformin and sufonylureas: meta-analysis of published observational studies.
Pladevall M; Riera-Guardia N; Margulis AV; Varas-Lorenzo C; Calingaert B; Perez-Gutthann S
BMC Cardiovasc Disord; 2016 Jan; 16():14. PubMed ID: 26769243
[TBL] [Abstract][Full Text] [Related]
19. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study.
Kim G; Jang SY; Han E; Lee YH; Park SY; Nam CM; Kang ES
Int J Cancer; 2017 Feb; 140(4):798-806. PubMed ID: 27861855
[TBL] [Abstract][Full Text] [Related]
20. Metformin in the prevention of hepatocellular carcinoma in diabetic patients: A systematic review.
Cunha V; Cotrim HP; Rocha R; Carvalho K; Lins-Kusterer L
Ann Hepatol; 2020; 19(3):232-237. PubMed ID: 31836424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
